Skip to content

Clinical trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in the United States with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Status: Unknown status Country / region: United States Clear all

38 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20013
20022
20031
20041
20054
20071
20082
20101
20121
20132
20141
20151
20182
20191
20201
20211
20221
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status38

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Colorado Blood Cancer Institute2
Gilead Sciences2
Herbert Irving Comprehensive Cancer Center2
Jonsson Comprehensive Cancer Center2
Medical College of Wisconsin2
Milton S. Hershey Medical Center2
University of California, Davis2
Alliance for Clinical Trials in Oncology1
Athenex, Inc.1
Boston Children's Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma38
Lymphoma22
Burkitt Lymphoma20
Lymphoma, Non-Hodgkin19
Leukemia, Lymphocytic, Chronic, B-Cell18
Lymphoma, Large B-Cell, Diffuse18
Lymphoma, Follicular17
Lymphoma, Large-Cell, Immunoblastic17
Lymphoma, Mantle-Cell16
Leukemia, Myeloid, Acute15

Trials

Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.